Suppr超能文献

稳定的胃十五肽BPC 157对大鼠野百合碱诱导的肺动脉高压的治疗可导致预防和逆转。

Stable Gastric Pentadecapeptide BPC 157 Therapy for Monocrotaline-Induced Pulmonary Hypertension in Rats Leads to Prevention and Reversal.

作者信息

Udovicic Mario, Sever Marko, Kavur Lovro, Loncaric Kristina, Barisic Ivan, Balenovic Diana, Zivanovic Posilovic Gordana, Strinic Dean, Uzun Sandra, Batelja Vuletic Lovorka, Sikiric Suncana, Skrtic Anita, Drmic Domagoj, Boban Blagaic Alenka, Lovric Bencic Martina, Seiwerth Sven, Sikiric Predrag

机构信息

Department of Pharmacology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, Croatia.

Department of Pathology, School of Medicine, University of Zagreb, Salata 11, P.O. Box 916, 10000 Zagreb, Croatia.

出版信息

Biomedicines. 2021 Jul 15;9(7):822. doi: 10.3390/biomedicines9070822.

Abstract

Monocrotaline selectively injures the lung's vascular endothelium and induces pulmonary arterial hypertension. The stable gastric pentadecapeptide BPC 157 acts as a prototype cytoprotective agent that maintains endothelium, and its application may be a novel therapy. Besides, BPC 157 prevents and reverses thrombosis formation, maintains platelet function, alleviates peripheral vascular occlusion disturbances, and has anti-arrhythmic and anti-inflammatory effects. Monocrotaline-induced pulmonary arterial hypertension in rats (wall thickness, total vessel area, heart frequency, QRS axis deviation, QT interval prolongation, increase in right ventricle systolic pressure and bodyweight loss) can be counteracted with early or delayed BPC 157 therapy. After monocrotaline (80 mg/kg subcutaneously), BPC 157 (10 μg/kg or 10 ng/kg, days 1-14 or days 1-30 (early regimens), or days 14-30 (delayed regimen)) was given once daily intraperitoneally (last application 24 h before sacrifice) or continuously in drinking water until sacrifice (day 14 or 30). Without therapy, the outcome was the full monocrotaline syndrome, marked by right-side heart hypertrophy and massive thickening of the precapillary artery's smooth muscle layer, clinical deterioration, and sometimes death due to pulmonary hypertension and right-heart failure during the 4th week after monocrotaline injection. With all BPC 157 regimens, monocrotaline-induced pulmonary arterial hypertension (including all disturbed parameters) was counteracted, and consistent beneficial effects were documented during the whole course of the disease. Pulmonary hypertension was not even developed (early regimens) as quickly as the advanced pulmonary hypertension was rapidly attenuated and then completely eliminated (delayed regimen). Thus, pentadecapeptide BPC 157 prevents and counteracts monocrotaline-induced pulmonary arterial hypertension and cor pulmonale in rats.

摘要

野百合碱选择性损伤肺血管内皮并诱发肺动脉高压。稳定的胃十五肽BPC 157作为一种维持内皮功能的细胞保护剂原型,其应用可能是一种新型治疗方法。此外,BPC 157可预防和逆转血栓形成,维持血小板功能,减轻外周血管阻塞紊乱,并具有抗心律失常和抗炎作用。早期或延迟给予BPC 157治疗可对抗野百合碱诱发的大鼠肺动脉高压(包括血管壁厚度、总血管面积、心率、QRS轴偏移、QT间期延长、右心室收缩压升高和体重减轻)。皮下注射野百合碱(80 mg/kg)后,每天一次腹腔注射(处死前24小时最后一次给药)或持续给予饮用水中直至处死(第14天或第30天)BPC 157(10 μg/kg或10 ng/kg,第1 - 14天或第1 - 30天(早期方案),或第14 - 30天(延迟方案))。未经治疗时,结果为完全的野百合碱综合征,其特征为右心肥大和毛细血管前动脉平滑肌层大量增厚、临床恶化,有时在注射野百合碱后第4周因肺动脉高压和右心衰竭死亡。采用所有BPC 157方案时,野百合碱诱发的肺动脉高压(包括所有紊乱参数)均得到对抗,且在疾病全过程中均记录到一致的有益效果。早期方案中肺动脉高压甚至未像晚期肺动脉高压那样快速发展,而晚期肺动脉高压迅速减轻然后完全消除(延迟方案)。因此,十五肽BPC 157可预防和对抗野百合碱诱发的大鼠肺动脉高压和肺心病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b27/8301325/c3acd425c49f/biomedicines-09-00822-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验